Blueprint to reduce wasteful blood transfusions

November 20, 2017

By analyzing data from randomized clinical trials comparing blood transfusion approaches, Johns Hopkins experts, along with colleagues at Cleveland Clinic and NYU Langone Medical Center, endorse recommendations for blood transfusions that reduce blood use to improve patient safety and outcomes. Publishing this week in JAMA Internal Medicine, the report also provides a how-to guide for launching a patient blood management program.

"In summary, there is no benefit in transfusing more blood than necessary and some clinical trials actually show harm to patients," says Steven Frank, M.D., professor of anesthesiology at the Johns Hopkins University School of Medicine. "All this does is increase risks and cost without adding benefit," he adds.

As defined by existing guidelines and the clinical trials reviewed, the report reinforces these recommendations:

Stable adult patients, including critically ill patients, with hemoglobin levels of 7 g/dL or higher should not be transfused. Patients undergoing orthopaedic or cardiac surgery, or patients with underlying heart disease with hemoglobin levels of 8 g/dL or higher should not be transfused. Patients who are stable and not actively bleeding should be transfused with a single unit of blood and then reassessed.

The clinical trials that were examined compared so-called liberal versus restrictive blood transfusions. Liberal transfusions are those given to patients with 9 to 10 grams of hemoglobin per one-tenth liter, or deciliter, of blood volume, while restrictive transfusions are those given to patients with 7 to 8 grams per deciliter. Many of the clinical trials examined by this team used the number of patients who died within a 30- to 90-day window post-transfusion as a measure of patient outcome.

Of the more than 8,000 patients included in eight clinical trials that were reviewed, there was no difference in mortality between liberal or restrictive transfusions. One clinical trial found an increased mortality associated with liberal transfusion, and occurrence of blood clots was increased in the liberal cohort in a study that involved traumatic brain injury patients.

"These recommendations don't apply to patients with acute coronary syndrome, severe thrombocytopenia and chronic dependent anemia, including sickle cell, because we didn't see enough evidence for patients with these conditions," says Frank.

The team also found that the largest randomized trials reduced the amount of blood used by 40 to 65 percent. Earlier this year, Frank reported the results of a four-year project to implement a blood management program across the Johns Hopkins Health System, reducing blood use by 20 percent and saving more than $2 million on costs over a year.

"As members of the High Value Practice Academic Alliance, we recognize the importance of promoting evidence-based recommendations for transfusion. Our analysis provides the evidence to reassure providers that restrictive transfusion practice actually improves patient care quality and safety, while yielding substantial reductions in health care expenditure and increasing the blood supply for patients with life-threatening bleeding," says Frank.
-end-
Funding for the blood management program at The Johns Hopkins Hospital was provided by the Johns Hopkins Health System and Armstrong Institute for Patient Safety and Quality. The authors are members of the High Value Practice Academic Alliance, a consortium of more than 80 partner institutions in the United States and Canada, with clinicians from 27 specialties and subspecialties working to advance high-value health care.

Authors on this paper:

Divyajot Sadana and Moises Auron of Cleveland Clinic Foundation; Ariella Pratzner, Harry Saag, Nicole Adler and Frank Volpicelli of NYU Langone Health; and Lauren Scher and Steven Frank of Johns Hopkins Medicine.

Johns Hopkins Medicine

Related Clinical Trials Articles from Brightsurf:

Nearly 1 in 5 cancer patients less likely to enroll in clinical trials during pandemic
A significant portion of cancer patients may be less likely to enroll in a clinical trial due to the ongoing coronavirus pandemic.

COVID-19 clinical trials lack diversity
Despite disproportionately higher rates of COVID-19 infection, hospitalization and death among people of color, minority groups are significantly underrepresented in COVID-19 clinical trials.

Why we should trust registered clinical trials
In a time when we have to rely on clinical trials for COVID-19 drugs and vaccines, a new study brings good news about the credibility of registered clinical trials.

Inclusion of children in clinical trials of treatments for COVID-19
This Viewpoint discusses the exclusion of children from coronavirus disease 2019 (COVID-19) clinical trials and why that could harm treatment options for children.

Review evaluates how AI could boost the success of clinical trials
In a review publishing July 17, 2019 in the journal Trends in Pharmacological Sciences, researchers examined how artificial intelligence (AI) could affect drug development in the coming decade.

Kidney patients are neglected in clinical trials
The exclusion of patients with kidney diseases from clinical trials remains an unsolved problem that hinders optimal care of these patients.

Clinical trials beginning for possible preeclampsia treatment
For over 20 years, a team of researchers at Lund University has worked on developing a drug against preeclampsia -- a serious disorder which annually affects around 9 million pregnant women worldwide and is one of the main causes of death in both mothers and unborn babies.

Underenrollment in clinical trials: Patients not the problem
The authors of the study published this month in the Journal of Clinical Oncology investigated why many cancer clinical trials fail to enroll enough patients.

When designing clinical trials for huntington's disease, first ask the experts
Progress in understanding the genetic mutation responsible for Huntington's disease (HD) and at least some molecular underpinnings of the disease has resulted in a new era of clinical testing of potential treatments.

New ALS therapy in clinical trials
New research led by Washington University School of Medicine in St.

Read More: Clinical Trials News and Clinical Trials Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.